3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Buy
60
MRES Quote, Financials, Valuation and Earnings
Last price:
$0.0200
Seasonality move
:
52.07%
Day range:
$0.0146 - $0.0225
52-week range:
$0.0001 - $0.0240
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
879.3K
Avg. volume:
916.4K
1-year change:
100%
Market cap:
$1.2M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingInstitute of Biomedical Research has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Institute of Biomedical Research has an estimated downside of -- from its current price of $0.0180.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $0.0180.
Fair Value
-
According to the consensus of 0 analysts, Institute of Biomedical Research has -- downside to fair value with a price target of -- per share.
MRES vs. S&P 500
-
Over the past 5 trading days, Institute of Biomedical Research has overperformed the S&P 500 by 9.37% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Institute of Biomedical Research does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Institute of Biomedical Research has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Institute of Biomedical Research reported revenues of --.
Earnings Growth
-
Institute of Biomedical Research has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Institute of Biomedical Research reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2008-12-31 | 2009-12-31 | 2010-12-31 | 2009-12-31 | 2010-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$452.7K | -$296.2K | -$50.2M | -$98.4K | -$18.1K | |
| EBITDA | -$378.8K | -$284.3K | $1.5M | -$98.4K | -$18.1K | |
| Diluted EPS | -- | -$0.03 | -$1.12 | -$0.02 | -- | |
| Period Ending | 2006-12-31 | 2007-12-31 | 2008-12-31 | 2009-12-31 | 2010-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $111.3K | $9.7K | $3.8K | -- | -- | |
| Total Assets | $111.8K | $84.8K | $84.1K | $74.7K | $654.6K | |
| Current Liabilities | $256.1K | $748.5K | $459.8K | $301.3K | $461.3K | |
| Total Liabilities | $256.1K | $748.5K | $459.8K | $301.3K | $461.3K | |
| Total Equity | -- | -- | -- | -$226.6K | $193.3K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2008-12-31 | 2009-12-31 | 2010-12-31 | 2009-12-31 | 2010-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $312.7K | -$280.2K | -$151.6K | -$97.9K | -$5.2K | |
| Cash From Investing | -$37.2K | -- | -- | -$15.2K | -- | |
| Cash From Financing | -$275.5K | $295.4K | $160.1K | $113.1K | $5.2K | |
| Free Cash Flow | $275.5K | -$295.4K | -$151.6K | -$113.1K | -$5.2K | |
MRES
Sector
Market Cap
$1.2M
--
Price % of 52-Week High
75%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
100%
--
Beta (5-Year)
2.581
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.0181
200-day SMA
Buy
Level
$0.0079
Bollinger Bands (100)
Buy
Level
0.0072 - 0.0072
Chaikin Money Flow
Sell
Level
-140.7M
20-day SMA
Buy
Level
$0.0120
Relative Strength Index (RSI14)
Buy
Level
67.2499
ADX Line
Sell
Level
34.9573
Williams %R
Neutral
Level
-25.1046
50-day SMA
Buy
Level
$0.0083
MACD (12, 26)
Buy
Level
0.0034
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
181.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based cannabinoids and mental health therapeutic research. The Institute has expanded its research to also include the augmentation of traditional medicine and the emerging science of medicinal mushrooms.
Stock Forecast FAQ
In the current month, MRES has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRES average analyst price target in the past 3 months is --.
-
Where Will Institute of Biomedical Research Stock Be In 1 Year?
According to analysts, the consensus estimate is that Institute of Biomedical Research share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Institute of Biomedical Research?
Analysts are divided on their view about Institute of Biomedical Research share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Institute of Biomedical Research is a Sell and believe this share price will rise from its current level to --.
-
What Is Institute of Biomedical Research's Price Target?
The price target for Institute of Biomedical Research over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MRES A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Institute of Biomedical Research is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MRES?
You can purchase shares of Institute of Biomedical Research via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Institute of Biomedical Research shares.
-
What Is The Institute of Biomedical Research Share Price Today?
Institute of Biomedical Research was last trading at $0.0200 per share. This represents the most recent stock quote for Institute of Biomedical Research. Yesterday, Institute of Biomedical Research closed at $0.0180 per share.
-
How To Buy Institute of Biomedical Research Stock Online?
In order to purchase Institute of Biomedical Research stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.06% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 7.03% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 0.89% over the past day.
